- $8.62m
- $7.82m
- $4.45m
Annual balance sheet for Biomerica, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
R2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | 2026 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.92 | 9.72 | 4.17 | 2.4 | 1.31 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.774 | 0.722 | 0.947 | 0.731 | 0.785 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 9.43 | 12.8 | 7.73 | 4.88 | 4.02 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.52 | 1.25 | 0.943 | 0.564 | 1.95 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 11.4 | 14.5 | 9.25 | 5.95 | 6.76 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.01 | 1.95 | 2.2 | 1.74 | 2.48 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.05 | 2.73 | 2.66 | 1.84 | 4.13 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 8.32 | 11.7 | 6.59 | 4.11 | 2.63 |
| Total Liabilities & Shareholders' Equity | 11.4 | 14.5 | 9.25 | 5.95 | 6.76 |
| Total Common Shares Outstanding |